We compared the levels of microparticles, platelet activation markers, soluble cell adhesion molecules, and soluble selectins between hypertensive patients with and without type 2 diabetes and control subjects. Binding of anti-glycoprotein IIb/IIIa and anti-glycoprotein Ib monoclonal antibodies to platelets did not differ significantly between the hypertensive patients and controls, but platelet expression of activation markers (CD62P, CD63, PAC-1, and annexin V) was higher in the hypertensive patients. Platelet-derived microparticle (PDMP) and monocyte-derived microparticle (MDMP) levels were significantly higher in the hypertensive patients than in the controls. Soluble ICAM-1, VCAM-1, P-selectin, and E-selectin levels were also higher in the
Introduction
The number of patients with diabetes mellitus has been rapidly increasing in Japan, although the number of hypertensive patients has not been increasing. However, it has recently been discovered that blood pressure control as well as glycaemic control is important to the management of diabetes mellitus. The UK Prospective Diabetes Study report 1 states that microvascular damage, including all diabetesmellitus-related events, such as death, cerebral apoplexy, and nephropathy, was found to be significantly suppressed in the group in which blood pressure was strictly controlled. Calcium channel blockers are widely used to treat hypertension and angina pectoris, because they provide effective coronary vasodilation, 2 and several studies have suggested an additional role for these drugs as anti-atherogenic agents, because they have been found to prevent the development of de novo angiographic lesions in human coronary arteries. 3, 4 Moreover, a variety of antiatherogenic mechanisms of calcium channel blockers have been assessed, including effects on platelet aggregation, 5 leukocyte-endothelial cell adhesion, 6 monocyte infiltration of the subendothelium, 7 permeability of the endothelium 8 and/or media, 9 and smooth muscle cell migration 10 and proliferation. 11 Expression of cell adhesion molecules is increased in both insulin-dependent and non-insulin-dependent diabetes mellitus, 12 and these molecules have been implicated in the microvascular complications of diabetes. E-selectin is an adhesion molecule involved in the adhesion of monocytes to endothelium. 13 It is expressed by endothelial cells at sites of atheroscrelotic lesions, 14 and serum levels of soluble E-selectin (sE-selectin) are elevated in diabetes mellitus. 12 Monocytes and macrophages have been suggested to play an important role in the development of atherosclerosis, 15, 16 and the first step in the process of monocyte infiltration into the subendothelial space is the adhesion of circulating monocytes to the endothelium. Macrophages are the predominant cell type in the lipid core of atherosclerotic plaques 17 and have been shown to express tissue factor. 18 Monocytes can synthesize procoagulant substances, although their ability to do so seems to be largely confined to tissue factor, 19 and the release of heterogeneous microparticles by endotoxin-stimulated monocytes has been suggested as a possible mechanism for regulating vascular cell functions. 20 These monocyte-derived microparticles (MDMPs) promote prothrombinase complex assembly, thus facilitating intravascular generation of thrombin and enhancing procoagulant activity. 21 Similar actions have been ascribed to various markers of platelet activation, such as platelet CD62P (plt-CD62P) and plateletderived microparticles (PDMPs). 22, 23 Thus, cell adhesion molecules, monocytes, and platelets all have an important influence on vascular events in hypertension complicated by diabetes.
The L-form of voltage-dependent calcium channels is found in heart muscle, smooth muscle, and skeletal muscle, and they function in excitementcontraction linkage (vasoconstriction, myocardial contraction reinforcement), whereas T-type calcium channels are found in the sinoatrial node and seem to be concerned with pacemaker activity. 24 Conventional calcium antagonists do not inhibit T-type calcium channels and are not expected to have a myocardial protecting effect. 24 Efonidipine, on the other hand, has a T-type calcium channel inhibitory effect in addition to its action on L-type calcium channels. [25] [26] [27] Efonidipine has been reported to appear to improve the capillary endothelial function of hypertensive patients, but few studies have investigated the effect of efonidipine on platelet and monocyte activation markers. The two purposes of the present study were: (1) to assess the role of monocyte activation markers, platelet activation markers, and cell adhesion molecules in vascular damage in hypertensive patients with type 2 diabetes, and (2) to evaluate the efficacy of efonidipine in preventing such vascular damage.
Materials and methods

Patients
The 48 patients admitted to our hospital between March 2000 and June 2001 for assessment of hypertension were recruited as subjects of this study. None of them had inflammatory, coronary artery, or cerebrovascular disease within the previous 3 months. None had clinically detectable renal, hepatic, infectious, or malignant disease. No anti-thrombotic agents, including aspirin, were administered. Although the patient's medications were not withdrawn, all patients abstained from taking any drugs for more than 12 h before blood sampling. Twentythree of the hypertensive patients had type 2 diabetes and 25 did not. All subjects gave their informed consent, and the study was performed according to the Declaration of Helsinki. The criteria for the diagnosis of hypertension was a recumbent systolic blood pressure of Ͼ150 mm Hg and a recumbent diastolic blood pressure of Ͼ90 mm Hg on two or more occasions. 28 Type 2 diabetes was defined according to American Diabetes Association criteria. 29 Thirty non-hypertensive controls were recruited from our hospital staff and others. None of the control subjects had any clinical evidence of ischaemic heart disease, diabetes mellitus, or cerebrovascular disease, and none were taking any medications. Table 1 shows the clinical characteristics of the hypertensive and control subjects.
Flow cytometry of activated platelets and microparticles
Blood samples were collected into tubes containing 3.8% sodium citrate (9:1 vol/vol). Platelet-rich plasma was prepared by centrifugation at 200 g for 10 min at room temperature. Washed platelets were prepared by centrifuging platelet-rich plasma at 1400 g for 10 min at room temperature. The pellet obtained was washed twice with washing buffer (9 mmol/l Na 2 EDTA, 140 mmol/l NaCl, and 26 mmol/l Na 2 HPO 4 , pH 7.2) and resuspended in Hepes-Tyrode's buffer (129 mmol/l NaCl, 8.9 mmol/l NaHCO 3 0.8 mmol/l KH 2 PO 4 , 0.8 mmol/l MgCl 2 , 5.6 mmol/l glucose, and 10 mmol/l Hepes, pH 7.4). An equal volume of 2% paraformaldehyde was added to the washed platelets, which were then incubated for 15 min at room temperature. Next, the platelets were washed twice, resuspended in stock solution (9 mmol/l Na 2 EDTA, 26.4 mmol/l Na 2 HPO 4 2H 2 O, 140 mmol/l NaCl, 0.1% NaN 3 , and 2% fetal bovine serum, pH 7.2), and stored at 4°C until analysed.
PDMPs were detected by a modification of a previously-reported method. 30, 31 An aliquot (10 l) of Control: non-hypertensive. Data are shown as means ± s.e.m. NS = not significant; BMI = body mass index; BP = blood pressure; WBC = leukocyte count; PLT = platelet count; UN = urea nitrogen; CRTN = creatinine.
platelet suspension (3 × 10 8 /ml) was added to 100 of Hepes-Tyrode's buffer containing 5 mmol/l EGTA, and both intact and aggregated platelets were removed by centrifugation at 1000 g for 15 min to yield a supernatant that contained only microparticles. The washed intact platelets (10 l, 3 × 10 8 /ml) were then added to the supernatant, and incubation with KMP-9 32 (a fluorescein isothiocyanate (FITC)-labelled monoclonal antibody directed against platelet GPIX) was performed for 30 min in the dark at room temperature. After incubation, samples were diluted 1:10 with Hepes-Tyrode's buffer containing 5 nmol/l EGTA and analysed with an Ortho Cytoron Absolute Analyzer (Ortho Diagnostic Systems, Tokyo, Japan). Only cells and particles positive for GPIX were gated in order to distinguish platelets and PDMPs from electronic noise. To differentiate between platelets and PDMPs, the lower limit of the platelet gate was set at the left limit of the forwardscatter profile of resting platelets. Ten thousand FITC-positive particles in the PDMP gate were then counted to determine the number of microparticles released per 10 000 platelets ( Figure 1 ). As an index of platelet activation, CD62P expression was quantified by immunostaining with an anti-CD62P monoclonal antibody (CLB-thromb/6, Immunotech, Marseille, France), CD63 (Immunotech), PAC-1 (Becton Dickinson, CA, USA) ( Figure 1 ). Platelet expression of glycoprotein (GP) IIb/IIIa and GPIb was detected with an anti-GPIIb/IIIa monoclonal antibody (NNKY1-32) 33 and an anti-GPIb monoclonal antibody (NNKY5-5).
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Figure 1
Flow cytometric analysis of PDMPs and histogram of activated platelets. Only cells and particles positive for monoclonal anti-GPIX antibody were gated to distinguish platelets and microparticles from electronic noise. To differentiate between platelets and microparticles, the platelet gate (PLT) was set in the upper square and microparticles in the lower square (PDMP). FITC-positive particles in the PDMP gate were then counted to determine the number of microparticles per 10 000 platelets. Washed platelets were treated with A23187. The fluorescence intensity of the various indicators (P-selectin, CD63, and PAC-1). Before: A23187 activation (−); after: A23187 activation (+).
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Assessment of MDMPs
MDMPs were detected by a slight modification of a previously reported method. 35 Washed intact platelets (10 l, 3 × 10 8 /ml) were added to plasma, and the mixture was incubated with an FITC-labelled anti-GPIX antibody and phycoerythrin (PE)-labelled CD14 for 30 min in the dark at room temperature. Samples were diluted 1:10 with Hepes-Tyrode's buffer containing 5 mmol/l EGTA and analysed with an Ortho Cytoron Absolute Analyzer (Ortho Diagnostics) that had been set to detect only particles bound to PE-CD14.
Measurement of selectins and cell adhesion molelules
Blood samples from the patients and healthy controls were collected into tubes containing sodium citrate or tubes without an anticoagulant. Blood was allowed to clot at room temperature for a minimum of 1 h, and serum or citrated plasma was isolated by centrifugation for 20 min at 1000 g and 4°C and then stored at −30°C until analysed. The positive controls for each assay were the recombinant products and standard solutions provided with the commercial kits. Serum selectin (E-and P-selectin) and cell adhesion molecule (intracellular cell adhesion molecule; sICAM-1, vascular cell adhesion molecule; sVCAM-1) levels were measured with a monoclonal antibody-based ELISA kit from R&D Systems (Toray Fuji Bionics, Tokyo, Japan) according to the manufacturer's instructions.
Administration of efonidipine
We administered efonidipine (Shionogi Pharmaceutical, Tokyo, Japan), 40 mg/day, to the hypertensive patients for 8 weeks. There were no changes in any of the other drugs taken by the patients during efonidipine treatment. The values of the above variables before and after efonidipine administration were compared.
Statistics
Statistical analysis was performed using the paired or unpaired t-test, and a P-value of less than 0.05 was considered statistically significant. Table 2 shows the levels of markers for resting platelets (GPIIb/IIIa and GPIb), activated platelets (CD62P, CD63, PAC-1, and annexin V), soluble cell adhesion molecules (sICAM-1 and sVCAM-1), and soluble selectins (sP-selectin and sE-selectin) in the control group and the hypertension group. There were no differences in the binding of anti-GPIIb/IIIa and anti-GPIb monoclonal antibodies between the two groups. However, there were differences in CD62P, CD63, PAC-1, annexin V, sICAM-1, sVCAM-1, sP-selectin, and sE-selectin between the hypertension patients and the controls. Figure 2 shows the levels of microparticles (PDMPs and MDMPs) in the control group and the hypertension group. There were significant differences in the levels of these particles between the hypertension patients and the controls (PDMPs: 545 ± 66 vs 358 ± 42, P Ͻ 0.01; MDMPs: 101 ± 39 vs 48 ± 15, P Ͻ 0.05). Table 3 shows the levels of platelet markers, soluble cell adhesion molecules (sICAM-1 and sVCAM-1), and soluble selectins (sP-selectin and sE-selectin) in the hypertension subgroups with and without diabetes. There were no differences in the levels of GPIIb/IIIa and GPIb between the two subgroups, but all of the markers showed significant differences between the diabetic and non-diabetic patients.
Results
As shown in Figure 3 , there were no significant differences in systolic pressure or diastolic pressure before efonidipine administration between the subgroups of hypertensive patients with and without diabetes, but both diastolic pressure and systolic blood pressure significantly decreased in both subgroups after efonidipine administration. Figure 4 shows the changes in platelet activation markers (CD62P, CD63, PAC-1, and annexin V) after efonidipine treatment in the subgroups of hypertensive patients with and without diabetes. All markers in the diabetes subgroup were decreased by efonidipine (P Ͻ 0.01 and P Ͻ 0.001), but none of them were changed by efonidipine in the non-diabetic subgroup. Figure 5 shows the changes in microparticles (PDMPs and MDMPs) after efonidipine treatment in the subgroups of hypertensive patients with and without diabetes. Both types of microparticles were decreased by efonidipine in the diabetes subgroup (P Ͻ 0.01 and P Ͻ 0.05), but were unchanged by efonidipine in the non-diabetic subgroup. Table 4 shows the changes in soluble cell adhesion molecules and soluble selectins after efonidipine treatment in the subgroups of hypertensive patients with and without diabetes. All markers were decreased by efonidipine in the diabetic subgroup (P Ͻ 0.01 and P Ͻ 0.05), but none were decreased by efonidipine in the non-diabetic subgroup. Figure 6 shows the changes in soluble adhesive molecules (sVCAM-1, sICAM-1, sP-selectin and sEselectin) in two groups with different systolic blood pressure responses to efonidipine treatment. The sVCAM-1 and sE-selectin values tended to decline after treatment in Group A, in which the systolic sICAM-1 = soluble intracellular cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecule-1; NS = not significant.
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Figure 6
Change of values of soluble adhesive molecules according to the response of the systolic blood pressure of hypertensive patients with diabetes to efonidipine administration. In Group A systolic blood pressure decreased 10% or more after efodipine administration (n = 13). In Group B systolic blood pressure decreased less than 10% after efodipine administration (n = 10). B. = before efonidipine administration A. = after efonidipine administration.
blood pressure decreased by 10% or more after the efonidipine administration, but not the sICAM-1 and sP-selectin values.
Discussion
The results of the present study showed that the levels of CD62P, CD63, PAC-1, annexin V, PDMP, MDMP, sP-selectin, and sE-selectin were elevated in the hypertensive patients, particularly in those with diabetes, and that some of these parameters were significantly decreased by administration of efonidipine. Hyperactive platelets may lead to capillary microembolisation secondary to the formation of microaggregates. 36 In the present study, we measured procoagulant PDMP, CD62P, CD63, PAC-1, and annexin V, and found that the levels of these platelet activation markers were significantly higher in the hypertensive patients than in the control subjects. Most clinical events associated with hypertension have a thrombotic component, and there have been several reports on platelet activation in hypertensive patients. [37] [38] [39] [40] Our results for CD62P, CD63, PAC-1, and annexin V support the findings in these reports. On the other hand, PDMPs play an important role in coagulation. Sims et al 41 found that C5b-9 and thrombin increased the number of binding sites for factor V on PDMPs. They also showed that PDMPs play a major role in the production of thrombin by the factor Va-Xa complex, and that these microparticles are responsible for the procoagulant activity of platelets. Thus, increased levels of PDMPs may cause hypercoagulability. Increased PDMPs are also observed in patients with uraemia and cerebral infarction, 42 and increased PDMP levels have been observed in disease states in which activated platelets have been detected in vivo. 30, 42 We previously reported significantly higher numbers of PDMPs in diabetic patients with elevated low-density lipoprotein (LDL) levels than in diabetic patients with depressed LDL levels, suggesting that PDMPs may participate in the development or progression of atherosclerosis in diabetics. 30 The present study also showed higher MDMP levels in the hypertensive patients than in the controls. Mesri et al 9 reported observing that co-culture of leukocytes with endothelium induces endothelial activation and inflammatory genes and that this process is mediated by the release of membrane microparticles by activated leukocytes. Our findings suggest that PDMPs and MDMPs may participate in the development of atherosclerosis in hypertension patients.
The results of the present study showed no differences in the binding of anti-GPIIb/IIIa and anti-GPIb monoclonal antibodies between the diabetic and non-diabetic subgroups of hypertensive patients, however, CD62P, CD63, PAC-1, and annexin V-positive platelets were increased in the diabetic subgroup compared with non-diabetic subgroup. Circulating levels of CD62P-and CD63-positive platelets have recently been shown to be elevated in patients with coronary artery disease or diabetes, 43 and our findings agree with those reports. The present findings with respect to PDMPs, MDMPs, CD62P, CD63, PAC-1, and annexin V also suggested that enhanced platelet activity and related procoagulant activity may induce hypercoagulability in hypertension patients with diabetes.
The present study also revealed increased MDMP levels in hypertensive patients with diabetes, and a relation between hypertension and monocytes has been reported previously. [44] [45] [46] Activated platelets stimulate the production of monocyte chemotactic protein-1 by monocytes through enhanced chemokine secretion and direct platelet-monocyte contact, which is mediated by expression of P-selection on the platelet surface. 47 Such a mechanism leading to enhanced expression of monocyte chemotactic protein-1 in leukocytes has recently been found in acute myocardial infarction patients. 48 We also studied the effect of efonidipine, a dihydropyridine phosphonate Ca 2+ channel antagonist, on CD62P, CD63, PAC-1, annexin V, PDMP, MDMP, sICAM-1, sVCAM-1, sP-selectin, and sE-selectin in hypertensive patients. Efonidipine is a drug with confirmed efficacy for the clinical treatment of hypertension and cardiac angina and for improvement of cerebral circulation. [25] [26] [27] Its principal mechanism of action has been found to be antagonism of voltage-operated calcium channels. 24 A beneficial effect of dihydropyridine calcium antagonists on endothelial function in hypercholesterolaemia has recently been reported, 49 suggesting that this drug may be useful for the prevention and treatment of arteriosclerotic disease. The results of the present study showed a significant decrease in CD62P-, CD63-, PAC-1-, and annexin V-positive platelets after efonidipine administration, and the levels of PDMPs and MDMPs, which are associated with platelet activation and monocyte activation, respectively, were also significantly decreased by efonidipine administration. PDMPs have procoagulant activity and are capable of generating thrombin, which induces platelet adhesion to endothelial cells and leads to vascular injury. 50 Efonidipine therapy may therefore be useful because of its antithrombin and anticoagulant effects, since it suppresses the production of coagulant factors by activated platelets. MDMPs are related to monocyte-derived coagulation activity, namely, tissue factor expression, and efonidipine seemed to also have an effect on monocytes-derived coagulation activity.
Some cell adhesion molecule levels were also significantly decreased by efonidipine administration. Subsets of monocytes and lymphocytes generally interact with each other and activate endothelial cells, and increased expression of endothelial adhesion molecules may promote vascular damage. These adhesion molecules include E-selectin, which is produced by endothelial cells, and P-selectin, which is a product of both endothelial cells and platelets, 51 and a relation to adhesive molecules has previously been reported in some hypertensive patients. [52] [53] [54] [55] In the present study, we found that Eselectin levels were significantly increased in the hypertension patients with diabetes. An increase in activated platelets and PDMPs, leading to monocyte infiltration of the arterial wall, has been suggested to be important in the development of atheroscler-osis. 56 Thus, the finding of a significant decrease in the levels of CD62P, PDMPs, and sE-selectin after treatment with efonidipine suggests that it may inhibit the vascular damage caused by the combination of hypertension and diabetes. The action of efonidipine on endothelial cells may be involved in mechanisms of action of efonidipine. Endothelial dysfunction, characterised by impaired endothelium-dependent vasoreactivity, is observed in type 2 diabetes. 57, 58 Together with other factors, altered bioavailability of nitric oxide, the most potent endothelium-derived vasodilator, contributes to the changes in vascular tone and integrity. 57 In addition to the impairment of vascular reactivity and permeability, other anti-atherosclerotic functions of nitric oxide are also diminished in hypertension, which may result in activated monocyte, leukocyte, and platelet adhesion to endothelium and increased platelet aggregation. 59, 60 Calcium antagonists may increase endothelial nitric oxide bioavailability by several mechanisms. 61, 62 Our results may be a reflection of the action of calcium antagonist on nitric oxide. However, further investigation is needed, because a pleiotoropic action of efonidipine cannot be ruled out.
In conclusion, the levels of platelet activation markers (CD62P, CD63, PAC-1, and annexin V), microparticles (PDMPs and MDMPs), soluble cell adhesion molecules (sICAM-1 and sVCAM-1), and soluble selectins (sP-selectin and sE-selectin) were significantly higher in the hypertensive patients than in the controls, and this tendency was significant in the hypertensive patients with diabetes. After administration of efonidipine to the hypertension patients, their levels of PDMPs, CD62P-, CD63-, PAC-1-, and annexin V-positive platelets, sICAM-1, sVCAM-1, sP-selectin, and sE-selectin all decreased significantly. Their MDMP levels also decreased, and the decrease was significant in the hypertensive patients with diabetes. These findings suggest that administration of efonidipine to hypertension patients with diabetes may prevent the development of cardiovascular complications caused by cell adhesion molecules or by activated platelets and monocytes.
